Skip to main content

Table 1 Summary of clinicopathological features of glioblastoma (CNS5) patients in the TCGA and CGGA cohorts

From: The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification)

 

TCGA

CGGA

Variables

Total (n=146)

High group (n=100)

Low group (n=46)

p

Total (n=173)

High group (n=38)

Low group (n=135)

p

Age

   

0.606

   

0.325

 <60

70 (48%)

46 (46%)

24 (52%)

 

114 (66%)

22 (58%)

92 (68%)

 

 ≥60

76 (52%)

54 (54%)

22 (48%)

 

59 (34%)

16 (42%)

43 (32%)

 

Sex

   

0.236

   

0.589

 Female

53 (36)

40 (40%)

13 (28%)

 

68 (39%)

13 (34%)

55 (41%)

 

 Male

93 (64)

60 (60%)

33 (72%)

 

105 (61%)

25 (66%)

80 (59%)

 

Radiation

   

0.918

   

0.298

 NO

20 (14%)

13 (13%)

7 (15%)

 

25 (14%)

3 (8%)

22 (16%)

 

 YES

126 (86%)

87 (87%)

39 (85%)

 

148 (86%)

35 (92%)

113 (84%)

 

Chemotherapy

   

0.524

   

0.016

 NO

35 (24%)

26 (26%)

9 (20%)

 

37 (21%)

14 (37%)

23 (17%)

 

 YES

111 (76%)

74 (74%)

37 (80%)

 

136 (79%)

24 (63%)

112 (83%)

 

MGMT promoter

   

0.593

   

0.248

 Methylated

51 (35%)

33 (33%)

18 (39%)

 

71 (41%)

12 (32%)

59 (44%)

 

 Un-methylated/Unknown

95 (65%)

67 (67%)

28 (61%)

 

102 (59%)

26 (68%)

76 (56%)

 

TERT promoter

   

0.008

   

-

 Mutant

41 (28%)

21 (21%)

20 (43%)

 

-

-

-

 

 Unknown

103 (71%)

78 (78%)

25 (54%)

 

-

-

-

 

 WT

2 (1%)

1 (1%)

1 (2%)

 

-

-

-

 

KPS

   

0.025

   

-

 <70

25 (17%)

22 (22%)

3 (7%)

 

-

-

-

 

 ≥70

88 (60%)

60 (60%)

28 (61%)

 

-

-

-

 

 Unknown

33 (23%)

18 (18%)

15 (33%)

 

-

-

-

 

Group

   

<0.001

   

-

 histoGBM

113 (77%)

89 (89%)

24 (52%)

 

-

-

-

 

 molGBM

33 (23%)

11 (11%)

22 (48%)

 

-

-

-

Â